Good day, ladies and gentlemen, and welcome to the Q4 2018 Ventas Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this call is being recorded. I would like to turn the call over to Juan Sanabria. Please begin.

Thanks, Michelle. Good morning and welcome to the Ventas conference call to review the company's announcement today regarding it's results for the year and quarter ended December 31, 2018. As we start, let me express that all projections and predictions and certain other statements to be made during this conference call may be considered forward-looking statements within the meanings of the federal securities laws. The company cautions that these forward-looking statements are subject to many risks, uncertainties and contingencies, and stockholders and others should recognize that actual results may differ materially from the company's expectations, whether expressed or implied. Ventas expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any changes in expectations. Additional information about the factors that may affect the company's operations and results is included in the company's Annual Report on Form 10-K for the year ended December 31, 2017 and the company's other SEC filings. Please note, the quantitative reconciliation between the non-GAAP financial measures referenced on this conference call, and it's most directly comparable GAAP measures, as well as the company's supplemental disclosure schedule are available on the Investor Relations site on our website, www.ventasreit.com. I will now turn the call over to Debra A. Cafaro, Chairman and CEO of the Company.

Thank you, Juan. We're very happy to have you join us on this side of the table for your first call. And good morning to all of our shareholders and other participants, and welcome to the Ventas year-end 2018 earnings call. I'm delighted also to be joined on today's call by my outstanding Ventas colleagues. In 2018 Ventas extended it's two-decade track record of sustained excellence. We delivered positive total return to our shareholders, substantially outperforming both REIT index and the S&P 500. We increased our dividend, harvested proceeds from successful investments that we redeployed to enhance balance sheet strength and invest in future growth. We added selective premiere private pay assets to our portfolio and we built a high-quality research and innovation development pipeline exceeding $1.5 billion with leading research universities. Importantly, we also enhanced and expanded our relationships with key industry partners; Wexford, TMB, Ardent, Atria and Sunrise during the year, and we crafted new beneficial arrangements with care providers, including Brookdale and ESL. In addition to achieving these strategic objectives, we also delivered on our financial goals. 2018 normalized FFO per share with $4.07 at the high end of our improved expectations on a best-in-class balance sheet. During the year, we were gratified that our team and our company were recognized repeatedly for our track record of our performance, our significant contributions to the industries where we have a major presence, and for our leadership in environmental, social and governance matters. Along the way, our Ventas team remained strong, smart, and unified. While I'd love to elaborate on our 2018 accomplishments, they are well described in today's release. Instead, allow me to outline our expectations for 2019, highlight some of our key opportunities for the year, and describe our commitment to returning to growth. We entered 2019…

Thank you, Debbie. I'm happy to report another solid year performance from our high-quality portfolio of healthcare, seniors housing and office properties. Our total property portfolio delivered same-store cash NOI growth of 1.2% for the full year 2018, above the midpoint of total company same-store guidance. In 2019 we expect our total portfolio same-store NOI growth to range between 0% and 1% benefiting from diversification of asset class operator, geography and business model. Let me detail our 2018 performance in 2019 guidance for our properties at a segment level starting with triple-net. We were very pleased by the performance of our triple-net portfolio which grew same-store cash NOI by an excellent 0.6% for the full year 2018. In the fourth quarter, triple-net same-store cash NOI increased to solid 2.1%. Across our total triple-net lease portfolio trailing 12 months EBITDA cash flow coverage for the third quarter of 2018, the latest available information was stable from the prior quarter at 1.5 times. Within that, seniors housing remained flat at 1.2 times while LTACs remain consistent at 1.4 times. As we predicted, performance at the assets for our Kindred LTACs improved in the second half of 2018 with operational strategies taking hold to mitigate LTAC criteria. We expect this improvement to continue in 2019. Also, Meditech [ph] just recommended a rate increase for LTACs recognizing their value in the healthcare delivery system. Meanwhile, Ardent's third quarter 2018 results were strong and the fourth quarter showed continued momentum. Ardent recently filed for an IPO. Ardent's red coverage remained robust at 2.9 times, and hospital medicare rates increased approximately 3% effective in the fourth quarter of 2018. As we look at 2019, triple-net same-store NOI is projected to grow, albeit at a more modest rate. Rent escalators are assumed to be partially offset by…

[Operator Instructions] Our first question comes from Nick Joseph of Citi. Your line is open.

Thanks. What's assumed the guidance for the timing of the asset sales in the loan repayments?

The $500 million in dispositions and loan repayments is really backend weighted. The loan repayments open really beginning in the summer. Sorry, guys is really midpoint of that back half.

Okay, thanks. As you think about 2019 being a pivot year, where will you enter 2020 on a run rate basis from a quarterly FFO perspective? Obviously, the midpoint suggests $0.95 a quarter but it will be variable given those loan repayments and contribution from development and redevelopment.

Yes. So, you're right to point out in terms of phasing for the year quarter-to-quarter, we certainly would expect in the second half sequentially to see lower FFO per share and that is indeed the case here. I wouldn't say wildly different, but it does trend down over the course of the year based on the time of the dispositions which again, are uncertain. So, it's hard to say exactly quarter-by-quarter what that's going to look like.

Thanks. There's the return to growth more of 2021 comments in 2020.

Nick as we said, we're intently focused on returning to our historical growth and the timing is not easily predictable within a specific quarter or so. But we know we're going to get there, we know what we have to do and we know how to do it. So I feel good about that.

Our next question comes from Josh Dinerlane [ph] of Bank of America. Your line is open.

Good morning. You mentioned that your team has been underwriting acquisitions. I know you have nothing in guidance. Where's the team most active? Is it senior housing, MOBs and other segments?

Well, clearly, we've been very busy building this great research and innovation pipeline, and I think John Cobb and his team for that, in terms of looking forward, I would say there's a combination of across our verticals, a combination of regular way type potential investments as well as more opportunistic type things that may come into focus over time.

Okay. And then on the Wexford, the 10 projects you've identified, is that kind of the lifespan of the contract being extended to 2029 or is it kind of just what you have in the near-term kind of lined up?

Yes, it is, John. It's in the near term. It's not in the next 12 months.

It's in the next couple of years.

So what do you think you can kind of do per year? Like two or three of these projects? And get runway [ph].

Well, the $1.5 billion typically 24 months, 18 to 24 months to start to finish, to open the building. And then a couple of years to stabilize from the air depending on they are pre-leasing; so that's how you should think about the phasing of the $1.5 billion.

Our next question comes from Nick [ph] of Scotiabank.

Good morning everyone. Just following up on Wexford, is there any -- you talked about the 18 to 24 months start to finish. Is there a way you can get a feel for future start assuming for this year and next year? Because I go back to the disposition guidance, it talks about $500 million there, which would be used for development and redevelopment. And based on your current pipeline and supplemental, you don't have that much spending. It looks like you have like another $250 million or 300 million of starts. That would be maybe as soon this year. So just give us a little feel for that

Just directionally I would say some starts in 2018, the backend weighted and then a ramp in 2020 and some spend thereafter.

I build on that and they can turn to the $500 million of development or redevelopment spend forecast this year, call it 70% of that is in fact development. And indeed, the majority of that is behind the pipeline just announced. So really this is about accelerating that pipeline beginning of this year.

And then Debbie, I wanted to go back to -- when you're talking about external growth, you're saying current market conditions are good for creative external growth. And I guess I'm just wondering, you have been a little bit quiet on the larger portfolio acquisitions in the last year, some of which have traded. How much was your -- you know cost of equity a factor in that? And that without the stock price where it is yeah up symmetrically versus is a low point in 2017. How much is that also affecting your -- you know thinking on the ability to do accretive acquisitions?

Right. And well, as I said, I mean, we're excited about the investments we're making in Research & Innovation. I do think the environment is more conducive and it really is around the fact that we may be seeing a slight upward drift in cap rates, and therefore, rewarding our patients coupled with an improved cost of capital. And then there are certain, again, more opportunistic things that come and go and where perhaps over time those could become more interesting to us. So it's a variety of factors.

Just one last question, Bob. I wanted to follow up. When you gave the Triple-Net segment guidance, you talked about some -- certain lease modifications with senior housing operators. But I think you said it -- that did not include Holiday. Is that correct?

That is correct, yes.

And I know you also talked about there's a lot of different scenarios with Holiday, but you expect to be made substantially economically whole. I guess the question I have though is that, there is some significant straight-line rent associated with lease. So I mean, is there still a chance that -- I mean, how should we think about an economic issue versus a GAAP FFO issue where there is some potential for a straight-line rent reduction if you had to restructure that lease?

I'll take that one. There are -- there's again a wide array of options, many permutations. We're looking rightly, as you said, at being made substantially economically whole. We do have structured guarantor, his credit has been directionally improved as a result of the other transactions. And so, we're really looking at it from an economic basis right now and then the GAAP impacts and so on are -- will follow depending on whether we do a transaction, if so, what that looks like and that -- the GAAP will follow whatever transaction if any we do.

Our next question comes from Steve Sakwa of Evercore.

I guess, I just wanted to talk maybe about some of the timing of deliveries. I think some of the delivery dates got pushed out a little bit. I mean -- just what are you seeing on the construction front and how do you sort of see the delivery timetables maybe changing over the next one to two years?

So in terms of deliveries, we take the NIC data and we then risk-adjust that should I say, based on our experience of how long it typically takes to deliver. And in fact that trend has been lengthening i.e. it's been taking longer than normal. I think we were pretty accurate in our forecast for '18 in terms of those deliveries. And as we looked at '19 -- as we look at '19, we expect to have similar levels in our portfolio of new deliveries as we saw in '18. Obviously, the trend-down in starts is encouraging as we said. That gives us some visibility now into '20. Of course, that -- that will be a function of timing of deliveries, but we do expect, based on the starts trend, which has been so favorable to see in 2020, a reduction in the amount of deliveries. So -- hence some of the commentary around the improving trends that we see over time in Seniors Housing.

And I guess maybe just to stay on that business, kind of the wage issues. I think you said expenses might grow 2% to 3% and embedded in that might be slightly higher wage growth. Just what kind of comfort do you have around sort of the wage component and that -- not putting upward pressure on overall expense growth in 2019?

Yes, this has been a pretty consistent theme, Steve. I think I asked the same -- got asked the same question this time last year. Wages have clearly been under pressure, no doubt. Tight labor market, we're all aware of that, minimum wage et cetera. What the operators have done is a phenomenal job of cost control, whether that be a business model, the operating model, how they staff managing indirect costs et cetera. And so, if you look at our full year, for example 2018 operating expense grew 2.5%, that's right in the midpoint of the range we've just given for '19. Our operators believe they have continued opportunity runway for cost control. But that is certainly necessary in light of the wage pressure as you point out.

And then last question on the -- on the R&I business. I guess the ASU deal, it sounds like half of that is at least going to the university. I guess, are your expectations that the other half would go to a traditional kind of life science type tenants or would you expect university to take the other half over time, and what are your prospects or pipeline look like from leasing up the balance of that building?

Sure, this is John. Historically speaking, we target the private sector like you said, but we have had a lot of -- where the university does take additional space, it just happened to us in -- at our Washington building that we just completed and successfully filled up. So we target both and our prospects are good.

Our next question comes from Andrew [ph] of Goldman Sachs.

Thanks for taking my question. Really fast, something I got this morning that I didn't know the answer to. 12% of your SHOP in the fourth quarter was outside of the same-store pool. And I think I modeled this wrong. First, you have that new line, the 16 properties intended for disposition, on page 2. I'm guessing that's outside of the same-store pool?

Yes.

That's correct.

It -- any sense of how that portfolio trended in '?18

Sure. So first of all, in terms of the same-store pool I just -- I'll just emphasize again, the ESL assets going into the full-year pool in the 2019, they're not in the full-year pool in 2018 as we transition them. So that's the biggest driver, 80% of our assets, that said, even before you are selling in same-store. We do have some assets, which are actively marketing incentive for disposition, is the term we use. Typically in Seniors Housing specifically, these may be in some higher supply markets and so the trends would mirror those types of markets.

So I don't want to put words in your mouth, Bob, but probably that -- I just did look -- if you look at it, there is only $1 million of NOI and $20 million of revenue that, that was probably a portfolio or assets that were pretty tough in '18?

Those have trended down very consistent with the market.

And then my second one, you mentioned ESL. If you broke your same-store portfolio in '19 between ESL and non-ESL, would there be a difference in the expectation for performance?

And perhaps a chance as to discuss ESL little bit. The last call we mentioned, they stabilized. We saw good fourth quarter from ESL really on the cost side in particular, getting their operating model in place. So nice stabilization of performance there. In terms of the impact in '19 in the same-store pool, that's a positive impact to the overall by about 60 basis points in the same-store pool overall. So put another way, you can adjust the same-store midpoint by that amount if you excluded it.

Got it. So basically -- so there is a bit of an easy comp if you will, where your SHOP can do better than kind of a generic SHOP portfolio in the US because of the ESL portfolio?

Well, we -- I would just say that, we expect this to have a positive contribution and that's what we intended when we moved the asset.

Our next question comes from John Kim of BMO Capital Markets.

Good morning. In your supplement, you provided what looks like new -- a new line of 8% to 12% range and stabilized returns on incremental capital.

Yes.

Just clarify, is that development yield or an IRR figure?

It's an unlevered yield on incremental capital, John. Good morning. I'm glad people are noticing some of our good additional disclosure and I'm glad it's helpful. But that's kind of -- that's an unlevered yield on incremental invested capital at stabilization.

And is that pertaining just to redevelopments or does that include developments alone?

That's the redevelopments, John. Specifically on that page, you'll see at the bottom for the redevelopments. Developments, we show expected stabilized yields specific to the projects.

I think previously you stated that your life science land bank can provide up to $2 billion of developments. And in today's press release, I think $1.5 billion. So, besides the ASU project, what was incrementally new as far as projects that you agreed upon?

And one thing we did say is that with the 10, sort of half are with new relationships, roughly have with existing ones. I'm glad you remember that we do have a land bank with some of our better universities that could support about $2 billion of development. And to tie that altogether...

Yeah, the half rule of thumb applies as well in terms of that land bank that we quoted going toward -- half of it roughly is going toward this new pipeline. That still remains as an opportunity.

Okay. And then Debbie you mentioned on an answer to previous question that opportunistic things come and go. Can you just maybe provide some more color on that, does that this specifically mean public opportunities?

Right. I mean almost by definition, opportunistic is a little bit come-and-go, to use your words. It is more expansive in terms of things where we have a unique insight or we have a unique relationship that we can employee to capture an opportunity that is unique.

Our next question comes from Jordan Sadler of KeyBanc Capital Markets.

Thank you. Good morning. Could you clarify on the ESL piece? Did you say it's a 60 basis point positive contribution to the overall or just to the SHOP piece?

To the SHOP same-store piece, not overall Company.

Okay. I thought so.

Yes.

And then as it relates to SHOP NOI trending throughout the year, we were talking about sort of the sequential trend in maybe FFO, but I was kind of curious, I think, it feels like your toughest comps are probably earlier in the year and -- so I would expect some sort of gradual improvement at the year, is that how you guys are thinking about it?

Actually, we think it's likely to be pretty consistent throughout the year. Forget seasonality, I'm just seeing year-over-year performance. Some of the things notable last year in the first quarter were the flu. This year we have, as I said, an easier flu albeit above normal levels, but severe weather is kind of a new factor in the mix in Q1. But as we look out over the course of the year, I don't see anything that spikes any particular quarter, frankly on a year-over-year basis.

And then just on the acquisition [indiscernible] opportunities, are there any particular segments that are sort of cropping up as having better or worse opportunity? Has your interest level in Senior Housing picked up at all, given sort of -- the fact that we're getting closer toward the ramp and the demos and possibilities in penetration?

This is John. I think it's across the board, we're seeing in all the sectors that we look at.

Is there anything that you could point to that's driving that, is it just more willing sellers or prices or...?

I think we are -- as Debbie said earlier, I think we're seeing a little bit uptick in yields. So that's making some of it more attractive, but sometimes deals just come to market.

Our next question comes from Derek Johnston of Deutsche Bank.

For Senior Housing, are you seeing better supply net demand dynamics in major metro markets versus secondary or suburban? And really how economically viable is Senior Housing in markets like New York City and San Fran where costs seem somewhat prohibitive?

Sure. So in terms of supply demand, we -- it's really a market by market conversation. I quoted a few in the past of the -- of the major or primary markets like Atlanta, Chicago, where we have seen a significant amount of supply demand, that continues. Secondary markets, if you just look at the segmentation in our supplemental, you can see it does have -- well, it feels a little bit like a more significant impact in terms of supply. Some of the smaller markets Salt Lake City et cetera, but it really is a market-by-market conversation. And again, I think just pivoting back to the overall trend downward, it's -- and starts is the encouraging piece that we keep wanting to point to. It's clearly as we look at 2020 kind of toward the tail-end coming down in terms of delivery expectations. So that's really good news.

Okay, got it. And just quickly from my second one. Could you just talk about the West Coast strategy and the expanded relationship or continued with PMB, and ultimately how Sutter is progressing and any updates there?

I would say that we are running the West Coast assets. We have been lucky enough to be partners with PMB that is a very well-known West Coast developer of high-quality medical office and outpatient and weak, we recently extended that relationship. It's been a very positive one. And they continue to have a good pipeline of development opportunities and we have an exclusive pipeline arrangement with them. Sutter as you point out is one, and it is -- I've just visited it during NAREIT, I believe and it's looking great and ready for occupancy and right across from a $2 billion new hospital that Sutter is moving into shortly. So we're excited about that one and we look forward to taking investors there as soon as we can.

Our next question comes from Chad Vanacore of Stifel.

This is Seth [ph] on for Chad. First question, looking at the dispositions, do you guys -- is there any update on the $30 million of rent that was associated with Brookdale, is that most of the $500 million disposition included in guidance? And have you identified those properties and any insight on timing or expected yields?

Yes. So good question. So, as you recall as early in 2018, we get a very attractive arrangement with Brookdale that extended our leases and also targeted about $30 million of rent for disposition, added 6.25% yield to Ventas. We have identified an early tranche of those potential dispositions and that is part of the $500 million to which Bob referred. And we're at the very early stage of marketing that portfolio and that's where we stand and that will continue to improve the overall quality of our portfolio and be helpful to Brookdale as well.

You know I would add, the loans are, I call it $300 million, $350 million [ph] of that overall total.

Loan repayments represent the rest of it. Yeah.

Got it, thanks. And then when we look at last quarter and we talked about your preliminary SHOP outlook, it was pretty much the same as '18. It seems like the upper end of that range was improved. Was that predicated on the outperformance of ESL or overall supply demand dynamics or just any more color that give you confidence that it's going to -- a possibility of improvement in '19?

Yes, great question. I'd highlight a few things and this dramatically applies not just to '19, but as we think about '20 and beyond. One of the things we have seen is solid occupancy. And I noted 10 basis point gap versus prior year which had narrowed throughout the year in 2018. And in fact, sequentially we grew occupancy in the fourth quarter for the first time since 2015. So there is something going on that's very positive on the occupancy side. I think it's market share gains and penetration. But that's really one of the things we find very encouraging. ESL you rightly point out, is another. And then the third, I would highlight is redevelopments. We have redevelopments in our same-store pool. I mean, we are seeing some lift from the redevelopments in '19 and in the '20s. So to give you a few of the ideas that gave us that confidence and the midpoint improving in '19 and then beyond.

Our next question comes from Jonathan Hughes of Raymond James.

Good morning and thanks for the added disclosure throughout the stuff, really appreciate it.

Right.

On the external growth front, earlier you mentioned pricing for deals has drifted up, that was on Nick's question. Not sure if that was specific to certain healthcare real estate asset class or just a broad comment, but would you care to maybe quantify that rise with specific emphasis on the MOBs? Have they may be moved up to 20 bips, 25 bips over the past six months, nine months?

Again, it's just -- we're starting to see a slight drift upward and it really is in several of the asset classes. And so I think you're on the right track.

Okay, fair enough. And then I haven't -- I don't think we've talked about Ardent in detail yet, but in the past you really wanted to expand that platform. There was a recent acute care deal granted outside of the US, but curious if you looked at that and then maybe where you're seeing any hospital or acute-care opportunities within the U.S.?

So as you know, high-quality health systems and I'll just point to HCA as a public example of that -- has done have the opportunity to continue to do well. We certainly have a great position within the health system market, it's a large market. And I think we would be very interested in continuing to grow that business if the right opportunities present themselves. We said at the beginning and continue to believe that we will be very selective in any investments we make in the space as we have been to-date. And we will remain opportunistic, that scenario where I think we will be disciplined and selective, but opportunities that could arise, we are in a good position to capture.

Are you hoping any international acute care opportunities?

We have looked at acute care opportunities abroad over time, and it obviously depends on the market and the yield after currency and taxes and whether we think it's a good risk adjusted return. But we have looked at opportunities outside the US and quality health systems over time.

And then -- and then just one more from me. And I realize there were some accounting changes over the past few years, so this is a big cosmetic, but year G&A has gone up a good amount over the past few years while the asset base has remained fairly stable. And I know this is going to be impacted by accounting change again this year. But I was hoping you could maybe steer us to a good maybe growth number on last year's G&A line item, not guidance, but just a suggestion of maybe what we can kind of expect this year. Thanks

Sure, I'll take that one. G&A in the '18 v '17 really follows the good performance that we had in '18. So it's really a function of incentives. Staffing has been quite stable and we continue to be very lean as we think about it and that's a variable therefore that moves around every year. I would start with inflationary sort of increase. On a normalized base as you point out, adjusted for accounting type impacts inflationary increases '19 v '18.

Our next question comes from Tayo Okusanya of Jefferies.

Thanks for the additional disclosure. I'm going to give all credit to Bob because Juan just thought it was huge.

It's all Juan's doing.

Anyway I wanted to focus on SHOP a little bit this morning. The first thing is just the RevPAR trend, 1% this quarter, 1.8% last quarter, about 3.1% a year ago. I just wanted to -- could you just talk a little bit just about what's happening with pricing power? I couldn't help but fixate on your commentary about -- for new leases that is going to be a negative mark-to-market there, which seems to fly in the face of some of the data we've seen from NIC.

Yes, so, I love this topic, Tayo. I wouldn't focus on the NIC data, it really doesn't look at apples-to-apples, it's not actual rates and it's tough to divine certainly in our opinion. For our data, though, we can see quite clearly the trend and the RevPAR has two components as you know. It has the in-place increases were residents that have been here year-over-year. And that we continue to see very nice pricing power on it. I mentioned north of 5% for those rate letters that just went out, and so that continues to be very encouraging with very few financial move-outs, by the way. What's driving that risk that you point out, rightly in terms of RevPAR over the course of the year, is the releasing spread. That has been in the mid-to-high single digits down versus previous resident and that is a function, of course, of new competition. And so on a blended basis, we point to 2019 in the 1% range for RevPAR. It really reflects those two factors. But it's blend frankly.

Thanks Tayo.

Okay, thank you very much.

I mean -- go ahead.

And then just one other point in regards to just that dividend outlook going into '19. Again when we kind of take a look at your guidance, make all the adjustments to kind of get to FAD, we kind of start getting to kind of like a mid-90%s type FAD dividend payout ratio. And just in light of that, wondering how you guys are thinking about the dividend?

Well, thank you for asking. The Board just increased the dividend in December and we feel very confident about our position relative to the dividend at the midpoint. It's in that low 80%s relative to normalized FFO. And as we said, we are committed to returning to growth and confident we can do so.

Our next question comes from Daniel Bernstein of Capital One.

I think nobody said hi to Juan. So I'll say hi to Juan. I thought I'd say during the Q2 given that he was out of the way, but... maybe next time.

Go ahead. We'll work at that, go ahead.

I'll just ask one question. So you've accelerated development on the life science side and I was wondering, did you see any potential for synergies between the MOB and life science development platforms given all of those university relationships, most of those universities have some very good hospital systems affiliated with them? Do you see any synergies to accelerate your MOB development as well?

Yes, it's a great question. So this is Pete Bulgarelli. Thanks for the question, Daniel. It's really a strategic focus for us. I mean there is an incredible overlap between our Research & Innovation portfolio and the opportunities with the MOB and the medical portfolio. And kind of in-between there is the academic medical function as well. So if you think about it typical, many of these universities we're working with, they have life science research, they also have med schools and they have academic medical facilities, and usually are leading research hospital. And so if we look at the opportunities, the cross-selling opportunities and the integration that we can do with those institutions, we see a lot of clear blue water.

Okay. That's all I have, given it's already 11, 11 o'clock. I'll hop off.

Thank you for being considerate. We appreciate it.

Our next question comes from Michael Carroll of RBC Capital Markets.

Bob, I wanted to touch on the $10 million rent adjustment you mentioned in your prepared remarks. Do you have the timing for those reductions and how many tenants that relates to?

Mike, it's Debbie. It's a handful of tenants and it would be throughout the year.

And did Ventas receive anything in return, I guess for doing those rent adjustments? And was there any discussion to move that to the management portfolio?

Right. As Bob said, this has not occurred, and so this is a bit of an estimate, our best estimate, albeit regarding our expectations for '19. While we've modeled it and forecasted as just a Triple-Net roll down estimate, as Bob said, there is a whole variety of things that might happen including, as you suggest, a transition of those assets to other operators and the management contract into our asset sales. And so that's -- we expect really for it to be a combination of those things. But the easiest way to think about it, was how we put it in the numbers, which is in Triple-Net.

And then last question related to the 2019 guidance, does the range include any non-recurring items similar to the Ardent prepayment fee that was recorded in 2Q '18?

No. Thank you for asking. We do not have fees or payments from tenants as we did last year.

Our next question comes from Lukas Hartwich of Green Street Advisors.

Hi. I'll just ask one. So, can you remind us what your plans are for the Ardent stake assuming that company does go public?

Well, we have about a $50 million investment in Ardent, and given the quiet period that Ardent's in, I would prefer to defer that discussion and tell another time.

Fair enough. All right, thank you.

Our next question comes from Todd Stender of Wells Fargo.

Hi, good morning. Thanks for squeezing me in.

We're happy to do it.

Thank you. So CapEx spend was up in Q4. Just looking at the office segment, it was about 22% of NOI, but more like 12% for the full year. Just I wanted to see what accounted for that spike in Q4. And then maybe what you're budgeting for 2019?

We do see typically in the fourth quarter a ramp on FAD. We saw that again that's true across the portfolio, including our Office. We saw that again this fourth quarter. And then as we look at the guidance for '19 in terms of FAD CapEx, that reflects really some increases from -- in the Office, in particular, from lease up and is a consequence of that, that's the biggest driver.

And then percentage of NOI, what's the fair number for 2019?

For which?

For the full year?

For the full year or just for the Office segment?

Mid-teens 15% or so.

And our last question comes from Michael Mueller of J.P. Morgan.

For the $10 million rent reduction that's in 2019, how different is that from the full annualized amount that will carry over into '20?

Again, it depends on when and how it's structured. There could be some potential carryover effect that would make it a little bit larger for '20, but immaterial basically.

Got it. Okay, that was it. Thank you.

All right. Well, thank you. I just want to thank everyone for their attention to Ventas and your interest in our Company. We appreciate it greatly. Our whole businesses continues to be driven by this great demographic demand and need-based diversified resilient long-term cash flows. And our team is really in great shape and we feel good about our relationships with our partners and care providers, our balance sheet, our opportunity for growth externally and our large and growing development pipeline of terrific Research & Innovation assets. So we're feeling good and we look forward to seeing all of you soon. Thank you.

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone have a great day.